Insider filing · NAMS
Johannes Jacob Pieter Kastelein
Chief Scientific Officer
profile →
NewAmsterdam Pharma Company N.V.
NAMS · Healthcare · 45 filings in 24 months
ticker →
Johannes Jacob Pieter Kastelein sold $3.4M of NewAmsterdam Pharma (NAMS)
Executed Aug 24, disclosed Aug 25, 1 day later.
Value, as filed
$3.4M
125,000 sh × $26.91
Executed
Aug 24
the trade date, as filed
Disclosed
Aug 25
1 day after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
JKJohannes Jacob Pieter Kastelein (Chief Scientific Officer) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in NewAmsterdam Pharma Company N.V. (NAMS). The largest single filing was $9.1M of NAMS (300,000 sh across 3 lots, as filed), executed Mar 5.
The name
NAMSHealthcare · NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with ca…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Johannes Jacob Pieter Kastelein in NAMS
NAMSSALE
NewAmsterdam Pharma Company N.V.
$1.3M50,246 sh × $25.03
Exec Sep 30
Filed Oct 2 · 4:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $9.1M
300,000 sh across 3 lots
Exec Mar 5
Filed Mar 9 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $1.6M
45,481 sh across 2 lots
Exec Feb 20
Filed Feb 24 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $200K
6,000 sh × $33.25
Exec Jan 5
Filed Jan 7 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $2.5M
100,000 sh across 3 lots
Exec Aug 21 2025
Filed Aug 25 2025 · 5:30 PM ET